Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

BACKGROUND: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. METHODS: A previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjermer, Leif, van Boven, Job F. M., Costa-Scharplatz, Madlaina, Keininger, Dorothy L., Gutzwiller, Florian S., Lisspers, Karin, Mahon, Ronan, Olsson, Petter, Roche, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725803/
https://www.ncbi.nlm.nih.gov/pubmed/29228950
http://dx.doi.org/10.1186/s12931-017-0688-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725803/
https://www.ncbi.nlm.nih.gov/pubmed/29228950
http://dx.doi.org/10.1186/s12931-017-0688-5

Ejemplares similares